文献综述
Copyright ©The Author(s) 2018.
世界华人消化杂志. 2018-12-08; 26(34): 2008-2017
在线出版 2018-12-08. doi: 10.11569/wcjd.v26.i34.2008
表2 HCC分子靶向药物临床试验研究进展
分类药品靶点对照临床试验阶段数量(总)OS (m)(药物/对照)结果参考文献
抗血管生成剂SorafenibBRAF, VEGFR, PDGFRPlacebo602(299/303)10.7 vs 7.9Yes[18]
SorafenibBRAF, VEGFR, PDGFRPlacebo226(150/76)6.5 vs 4.2Yes[19]
RegorafenibTIE2, VEGFR, PDGFRPlacebo573(379/194)10.6 vs 7.8Yes[24]
Lenvatinib(E7080)c-Kit, FGFR, VEGFRSorafenib951(478/476)13.6 vs 12.3Yes[26]
Sunitinibc-Kit, VEGFR, PDGFRSorafenib1074(530/544)7.9 vs 10.2termination[29]
BrivanibFGFR, VEGFRSorafenib1155(577/588)9.5 vs 9.9No[30]
BrivanibFGFR, VEGFRPlacebo395(263/132)9.4 vs 8.2No[31]
LinifanibVEGFR, PDGFRSorafenib10359.1 vs 9.8No[50]
RamucirumabVEGFR2Placebo553(277/276)9.2 vs 7.6No[33]
ApatinibVEGFR2-Ⅱ/Ⅲ121/3609.7 vs 9.8Yes/Ongoing[27,28]
mTOR抑制剂EverolimusmTORPlacebo546(363/184)7.6 vs 7.3No[36]
SirolimusmTOR-256.6No[38]
TemsirolimusmTOR-368.89No[39]
c-Met抑制剂Tivantinibc-MetPlacebo1071.6 vs 1.4Yes[41]
Tivantinibc-MetPlacebo3408.4 vs 9.1No[42]
Cabozantinibc-Met, RET, VEGFR,KITPlaceboⅡ/Ⅲ41/76011.5/-Yes/Ongoing[43]
Foretinibc-Met, TIE-2, VEGFR2Placebo45-Yes[51]
Golvatinibc-Met, VEGFR2Ⅰ/Ⅱ-Ongoing*
Capmatinibc-MetPlaceboⅠ/Ⅱ33/280-Ongoing*
Tepotinibc-MetPlaceboⅠ/Ⅱ21/140-Ongoing*
ERK抑制剂SelumetinibMEK1/2-194.2No[45]
Refametinib + sorafenibMEK-709.7Yes(RAS突变)[52]
PimasertibMEK1/2-Ⅰ/Ⅱ26-termination*
免疫检查 点抑制剂NivolumabPD1-Ⅰ/Ⅱ48/214-Yes[47]
TremelimumabCTLA-4-218.2Yes[48]

引文著录: 石娟娟, 党双锁. 肝细胞癌的分子靶向治疗. 世界华人消化杂志 2018; 26(34): 2008-2017